DGAP-News: STRATEC Biomedical AG / Key word(s): Half Year Results/Interim Report STRATEC accelerates growth in first half of 2014 23.07.2014 / 07:35 --------------------------------------------------------------------- STRATEC accelerates growth in first half of 2014 - Sales of EUR 69.1 million in 6M/2014 (+14.9%; 6M/2013: EUR 60.1 million) - EBIT of EUR 11.2 Million** in 6M/2014 (+36.0%; 6M/2013: EUR 8.3 million) - EBIT margin of 16.3%** in 6M/2014 (+260 base points; 6M/2013: 13.7%) - Consolidated net income of EUR 9.6 Million** in 6M/2014 (+47.3%; 6M/2013: EUR 6.5 million) - Earnings per share of EUR 0.82** in 6M/2014 (+46.4%; 6M/2013: EUR 0.56) Birkenfeld, July 23, 2014 STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX) today announced its results for the period from January 1, 2014 to June 30, 2014 upon the publication of its Interim Report as of June 30, 2014. <pre> Key figures (EUR 000s) 01.01.- 06.30.2014 01.01.- 06.30.2013* Change Sales 69,050 60,071 +14.9% EBIT 11,232** 8,257 +36.0% EBIT margin (%) 16.3** 13.7 +260 BPS Consolidated net income 9,635** 6,543 +47.3% Earnings per share (EUR) 0.82** 0.56 +46.4% </pre> * The accounting methods used in the consolidated financial statements were amended in line with IAS 8 in the 2013 financial year. Reference is made in this respect to the information in the Annual Report 2013 in Section A of the notes to the consolidated financial statements. ** 2014 figure adjusted to exclude a one-off item resulting from recognition in the first quarter of expenses for the remaining years of the term of a management board contract for a retired member of the Board of Management. Unadjusted EBIT amounts to EUR 10.3 million, the corresponding EBIT margin amounts to 14.9%, consolidated net income to EUR 8.9 million and earnings per share to EUR 0.76. The effective amount of the liability due may differ at the time of payment. Financial performance STRATEC generated sales growth of 14.9% in the first six months of the 2014 financial year. This sales performance, which remains slightly ahead of budget, was chiefly driven by growth with established systems. An increasing share of growth was also attributable to systems recently launched onto the market by our customers. The figures include a small positive financial effect, one set also to continue over the remaining quarters of the current financial year, resulting from the termination of a development and supply agreement announced in July 2013. Based on current planning, this monetary item will increase the EBIT margin for the 2014 financial year as a whole by around 30 basis points. Part of the substantial increase in second-quarter sales in percentage terms is also due to the basis effect in regards to the backlog in deliveries due to flood damages in the second quarter of 2013. EBIT for the first six months of 2014 amounted to EUR 11.2 million, corresponding to an EBIT margin of 16.3%. This further improvement in the EBIT margin - by 260 base points compared with the first six months of 2013 - was mainly driven by the positive development in the gross margin for high-volume systems and by growth in the volume of such systems sold. The margin also benefited from the ongoing slightly positive development in turnover with service parts. At EUR 9.6 million, consolidated net income was up 47.3%, and thus substantially ahead of the previous year's figure of EUR 6.5 million. The company generated earnings per share of EUR 0.82 (+46.4%). These figures have been adjusted to exclude a one-off item resulting from recognition in the first quarter of expenses for the remaining years of the term of a management board contract for a retired member of the Board of Management. On an unadjusted basis, EBIT amounted to EUR 10.3 million, consolidated net income to EUR 8.9 million, and earnings per share to EUR 0.76. Development in personnel Including temporary employees, the STRATEC Group's total workforce of 546 employees as of June 30, 2014 remained unchanged compared with March 31, 2014 and December 31, 2013. Project development, outlook and financial forecast In the current year, STRATEC is focusing on achieving further major development milestones, additional market launches, and finalizing negotiations for new development and production contracts. Furthermore, the expansion in the company's production and development capacities is set to play a key role in 2014. One example here is the planned construction of a proprietary development complex at STRATEC's location in Romania where, depending on the relevant permits being issued, construction work should begin before the end of the current financial year. For 2014, STRATEC continues to expect substantial sales growth compared with the 2013 financial year, accompanied by a slight increase in the EBIT margin. The medium-term financial forecast for the years through to 2017 provides for average annual sales growth of 8% to 12% based on the volume of sales generated in the 2013 financial year. The service parts division continued to develop stably at a slightly higher level than in 2013. The company has not yet witnessed any implications from current events in connection with the Ukraine crisis and sanctions against Russia. Our partners, who generally market our systems with their own reagents, have currently reported only a very low level of impact. Annual General Meeting At the Annual General Meeting held on June 18, 2014, the company's shareholders approved all of the agenda items. Among the other items, shareholders approved the distribution of a dividend of EUR 0.60 per share for the 2013 financial year (previous year: EUR 0.56). The dividend was distributed to shareholders via their depository banks from June 20, 2014 onwards and amounted to EUR 7.1 million in total. Since payment of the first dividend in 2004, STRATEC has thus increased its dividend for the tenth year in succession. Conversion in accounting methods The business results presented here represent consolidated figures following the previously announced amendment to accounting methods pursuant to IAS 8 (Accounting Policies, Changes in Accounting Estimates and Errors). The comparative figures for the previous year have been adjusted accordingly. The amendments to accounting methods are explained in detail in the 2013 Annual Report from Page 48 onwards. Among other factors, these voluntary amendments also involved converting the accounting method used to recognize projects, a measure resulting from a recommendation made by the German Financial Reporting Enforcement Panel (DPR) and whose implementation was completed at the end of 2013. Interim Report as of June 30, 2014 Further details can be found in our Interim Report as of June 30, 2014, which has been published today on the company's homepage at www.stratec.com/financial_reports. About STRATEC STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange. Further information can be obtained from: STRATEC Biomedical AG André Loy, Corporate Communications Gewerbestr. 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 ir@stratec.com www.stratec.com End of Corporate News --------------------------------------------------------------------- 23.07.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: info@stratec.com Internet: www.stratec.com ISIN: DE0007289001 WKN: 728900 Indices: TecDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 278902 23.07.2014
DGAP-News: STRATEC accelerates growth in first half of 2014
Top 10 Most Recent News Articles
EZaccessMD Data Breach: Class Action Lawsuit Looms
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026
A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...
Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control
Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...
Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut
Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...
Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact
A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...
Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake
Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...
Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market
A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...
Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit
High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...
Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives
Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...
Continue ReadingTop 5 Most Recently Viewed Articles
Blend's AWS Financial Services Competency Enhances Innovations
Blend Takes a Major Stride with AWS Financial Services Competency Exciting news emerges from Blend as the company secures a crucial recognition in the cloud technology arena. They've recently achieved the prestigious AWS Financial Services Competency badge, a testament to their outstanding expertise and remarkable track record in delivering innovative, secure, and...
Continue Reading
The Upcoming Surge of Last Mile Delivery Market Growth
Overview of the Last Mile Delivery Market Growth The Last Mile Delivery market is poised for significant growth in the coming years, projected to rise by USD 51.1 billion from 2025 to 2029. This increase is primarily driven by the expanding global e-commerce sector and the integration of advanced technologies, including AI, which are transforming logistical operations....
Continue Reading
Tide Rock Expands Its Precision Machining Horizons Through Acquisitions
Tide Rock Expands Its Precision Machining Horizons Tide Rock has taken a significant leap forward in the field of advanced precision machining through its recent acquisitions. By acquiring Precision Waterjet & Laser, now known as Precision Advanced Machining, located in Anaheim, California, and Made in America Manufacturing based in Buda, Texas, Tide Rock is enhancing its...
Continue Reading
Novavax Revises Projections, Anticipates Robust Nuvaxovid Demand
Novavax Reports Strong Second Quarter Results Recently, Novavax Inc. reported impressive sales of $239.24 million for the second quarter of 2025, marking a significant shift from $415 million during the same period in the previous year. This figure exceeded the Wall Street consensus expectations, which estimated sales at $156.29 million. Such growth highlights Novavax's...
Continue Reading
Insights into Novartis' Cosentyx and GCAptAIN Study Findings
Novartis' Groundbreaking Updates on Cosentyx in GCAptAIN Study Novartis has recently provided significant updates regarding the Phase III GCAptAIN study, focusing on the efficacy of Cosentyx (secukinumab) for patients suffering from giant cell arteritis (GCA). This condition, predominantly affecting older adults, poses a risk of severe complications if not managed...
Continue Reading